Boehringer Accelerates Adalimumab Dual Pricing Strategy With 81% Discount
Adds Deep-Discounted Unbranded Version Of Cyltezo Biosimilar Rival To Humira In The US
• By David Wallace
The unbranded adalimumab biosimilar offers an 81% discount to Humira • Source: Shutterstock 
